ArticleFrontiers in public health2026

Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis.

Shanshan Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.